Podcasts about Reimbursement

In this episode, Mark Domayhn, Partner at JD Lymon Group, joins Duane Mancini to unpack what medtech innovators often miss most: reimbursement isn't a box to check after FDA—it's the commercial foundation that determines whether hospitals and physicians can adopt your technology. Drawing on experience across Medtronic, Zimmer, and St. Jude/Abbott, Mark breaks down the “three-legged stool” of coverage, coding, and payment, why clinical evidence must satisfy payer standards (not just FDA), and how to “follow the money” across fragmented U.S. systems. The conversation then dives into the New Technology Add-On Payment (NTAP) program, why it matters for inpatient launches, how breakthrough designation has increased NTAP success, and the major implications of CMS proposing to repeal the alternative pathway—plus what companies can do before the June 9 comment deadline. Mark Domyahn LinkedInJD Lymon Group WebsiteRAPID Coverage Pathway InformationDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law and JumpStart Inc.

In this episode of Medsider Radio, we sat down with Karthik Ganesh, CEO of OnMed.OnMed is the healthcare technology company behind OnMed CareStation, a “Clinic-in-a-Box” designed to expand access to primary and urgent care. Before OnMed, Karthik served as CEO of EmpiRx Health, leading the company through rapid growth and a successful private equity transaction in 2021. Throughout his career, he's held leadership roles at QualCare, CareAllies, and Aetna, and advised healthcare organizations through Deloitte and EY.In this interview, Karthik discusses why hybrid care models still require a human touch, how enterprise healthcare buyers evaluate value propositions differently, why brand and culture should shape execution early, and how operating under constraints can sharpen innovation.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Karthik Ganesh, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:04) - Karthik's obsession with healthcare access, and the “broken doorway” problem behind OnMed (05:51) - How OnMed combines telemedicine and brick-and-mortar care into a “Clinic in a Box” (09:04) - The OnMed metrics that surprised Karthik most, including a 37% patient return rate, and the reasons behind the company's success (09:22) - What OnMed designed differently after realizing that patients approach healthcare with their guard up (15:27) - The pitfalls of B2C healthcare and how OnMed was built as a B2B company by intention (22:01) - How Karthik reshaped OnMed around clarity, structure, and high performers (30:23) - What “brand” actually means to Karthik (39:37) - How OnMed tailored its value proposition for payers, providers, employers, and universities (45:45) - Karthik's fundraising philosophy: constraints keep companies inventive

Most physical therapists know something's broken. Reimbursements are declining. Administrative burden is rising. And despite delivering massive value, the profession is still treated like an afterthought.In this episode of the Private Practice Owners Podcast, Nathan Shields sits down with Scott Gardner—clinic owner and leader of the United Physical Therapy Association—to unpack the real reason behind the industry's struggles.From the “ancillary provider” label to Medicare policy, Scott breaks down why physical therapists are stuck at the bottom of the healthcare hierarchy—and what it will actually take to change that.This isn't theory. This is a behind-the-scenes look at the legislative, financial, and systemic forces shaping your clinic's future.In this episode, you'll learn:Why physical therapists are still classified as “ancillary” providers—and why it mattersThe real reason reimbursements keep decliningHow Medicare policy directly impacts your clinic revenueWhat MPPPR is (and why it's quietly costing you thousands)The truth about “opting out” of MedicareWhy most therapists complain—but don't take actionHow advocacy and legislation shape the future of private practiceWhat needs to happen for PTs to gain autonomy and higher payWhy unity across clinics may be the only way forwardThis episode is not about quick wins. It's about understanding the system—and how to actually change it.

In this episode of Medsider Radio, we sat down with Dr. Connie Lehman, founder and CEO of Clairity.Clairity is the first FDA-authorized AI platform that predicts a woman's five-year risk of developing breast cancer using only a routine screening mammogram.A physician scientist with over 300 peer-reviewed publications, Connie is a Professor of Radiology at Harvard Medical School and Breast Imaging Specialist at Massachusetts General Brigham (on leave). She holds an MD and PhD from Yale and was named to Forbes' 50 Over 50 Innovators and TIME 100 World's Most Influential Leaders in Health.In this interview, Connie discusses her experience translating academic research into a commercially viable startup, the massive undertaking of generating clinical evidence when you're creating a new category, and how Clairity is approaching adoption on two fronts: fitting into physician workflows and building access pathways for patients.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Connie Lehman, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:04) - The broken screening paradigm Connie saw in clinic — and the gap that became Clairity (05:09) - How Clairity rolls the clock back from detection to predicting risk in healthy women (07:31) - Why "more data is better" turned out to be wrong and how that shaped Clairity's product scope (21:57) - How physicians can translate grant-generating discipline into building a company (24:56) - What 18 months of pre-sub meetings revealed about navigating a de novo pathway (26:49) - Why Clairity validated its technology in over 250,000 mammograms when FDA required far less (34:43) - How Connie flipped the natural question from "how can doctors offer this?" to "how can women access it?" (43:47) - How relationships, not pitches, drove Clairity's $43M Series B

Send us Fan MailHospice has always been about people, but the future of hospice will increasingly be shaped by data—and that shift is both exciting and unsettling.In Part Two of The Future of Hospice: How HOPE Will Transform Reimbursement & Care, Raianne Melton and Andrea Hale unpack how the HOPE tool could redefine hospice reimbursement, value-based care, and quality measurement across CMS, Medicare Advantage, and health systems. The conversation explores where hospice measurement may be heading—from symptom impact scoring and burdensome discharges to acuity tracking, HUV utilization, and the growing importance of consistent documentation and actionable clinical data.The episode also focuses on what hospice leaders can do now to prepare: improving point-of-care documentation, simplifying EMR workflows, leveraging real-time analytics, and exploring AI-powered ambient listening to reduce clinician burden while preserving compassionate care. Ultimately, this conversation is about helping hospice organizations prove their value with measurable outcomes while staying true to the mission that defines hospice care.This episode offers practical insights for hospice executives, nonprofit healthcare leaders, clinicians, and anyone navigating the evolving landscape of end-of-life care.Guest:Andrea Hale, CEO of Valley Hospice Raianne Melton, Director of Clinical Services of Professional Services for AxxessHost:Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of LeadershipThe Anatomy of Leadership podcast explores the art and science of leadership through candid, insightful conversations with thought leaders, innovators, and change-makers from a variety of industries. Hosted by Chris Comeaux, each episode dives into the mindsets, habits, and strategies that empower leaders to thrive in complex, fast-changing environments. With topics ranging from organizational culture and emotional intelligence to navigating disruption and inspiring teams, the show blends real-world stories with practical takeaways. The goal is simple yet ambitious: to equip leaders at every level with the tools, perspectives, and inspiration they need to lead with vision, empathy, and impact.https://www.teleioscn.org/anatomy-of-leadership

Hospice has always been about people, but the future of hospice will increasingly be shaped by data—and that shift is both exciting and unsettling.In Part Two of The Future of Hospice: How HOPE Will Transform Reimbursement & Care, Raianne Melton and Andrea Hale unpack how the HOPE tool could redefine hospice reimbursement, value-based care, and quality measurement across CMS, Medicare Advantage, and health systems. The conversation explores where hospice measurement may be heading—from symptom impact scoring and burdensome discharges to acuity tracking, HUV utilization, and the growing importance of consistent documentation and actionable clinical data.The episode also focuses on what hospice leaders can do now to prepare: improving point-of-care documentation, simplifying EMR workflows, leveraging real-time analytics, and exploring AI-powered ambient listening to reduce clinician burden while preserving compassionate care. Ultimately, this conversation is about helping hospice organizations prove their value with measurable outcomes while staying true to the mission that defines hospice care.This episode offers practical insights for hospice executives, nonprofit healthcare leaders, clinicians, and anyone navigating the evolving landscape of end-of-life care.Guest:Andrea Hale, CEO of Valley Hospice Raianne Melton, Director of Clinical Services of Professional Services for AxxessHost:Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of LeadershipTeleios Collaborative Network   /   https://www.teleioscn.org/tcntalkspodcast

Send us Fan MailThe future of hospice care is changing—and the HOPE assessment tool may redefine how providers deliver care, document outcomes, and receive reimbursement.Healthcare is entering a new era where quality outcomes, patient data, and accountability are driving the future of care delivery.  In this episode, we're joined by Andrea Hale, CEO of Valley Hospice, and Raianne Melton, Director of Clinical Services of Professional Services for Axxess, whose expertise and frontline perspective help unpack one of the most significant shifts happening in hospice today—the implementation of the HOPE assessment tool. Their insight provides valuable guidance for hospice leaders, clinicians, and organizations preparing for the future of reimbursement and patient-centered care.In Part One of this important conversation, we explore how the Hospice Outcomes & Patient Evaluation (HOPE) tool is poised to transform the hospice landscape.  From evolving CMS expectations to the growing emphasis on quality metrics and patient-centered outcomes, this episode breaks down what hospice leaders, clinicians, and healthcare organizations need to understand now.Join us as we discuss:• What the HOPE tool is and why it matters• How reimbursement models are shifting in hospice care• The operational and compliance challenges providers may face• Why documentation and quality reporting are becoming more critical than ever• How organizations can proactively prepare for the future of end-of-life careWhether you're a hospice professional, nonprofit executive, healthcare leader, or business decision-maker, this episode provides timely insight into the changing future of compassionate care delivery.Our Guest:Andrea Hale, CEO of Valley HospiceRaianne Melton, Director of Clinical Services of Professional Services for AxxessHost:Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of Leadership

The future of hospice care is changing—and the HOPE assessment tool may redefine how providers deliver care, document outcomes, and receive reimbursement.Healthcare is entering a new era where quality outcomes, patient data, and accountability are driving the future of care delivery.  In this episode, we're joined by Andrea Hale, CEO of Valley Hospice, and Raianne Melton, Director of Clinical Services of Professional Services for Axxess, whose expertise and frontline perspective help unpack one of the most significant shifts happening in hospice today—the implementation of the HOPE assessment tool. Their insight provides valuable guidance for hospice leaders, clinicians, and organizations preparing for the future of reimbursement and patient-centered care.In Part One of this important conversation, we explore how the Hospice Outcomes & Patient Evaluation (HOPE) tool is poised to transform the hospice landscape.  From evolving CMS expectations to the growing emphasis on quality metrics and patient-centered outcomes, this episode breaks down what hospice leaders, clinicians, and healthcare organizations need to understand now.Join us as we discuss: • What the HOPE tool is and why it matters • How reimbursement models are shifting in hospice care • The operational and compliance challenges providers may face • Why documentation and quality reporting are becoming more critical than ever • How organizations can proactively prepare for the future of end-of-life careWhether you're a hospice professional, nonprofit executive, healthcare leader, or business decision-maker, this episode provides timely insight into the changing future of compassionate care delivery.Our Guest:Andrea Hale, CEO of Valley HospiceRaianne Melton, Director of Clinical Services of Professional Services for AxxessHost:Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of Leadership

In this episode of Medsider Radio, we sat down with Antony Odell, co-founder and CEO of Echopoint Medical.Echopoint is a London-based UCL spinout developing iKOr, an optical microcatheter for coronary diagnostics.Antony brings over 30 years of medtech experience across Johnson & Johnson, Fresenius, and Stryker, before transitioning into startups as CEO of Tayside Flow Technologies and Tissue Regenix. He holds a BSc in Physiology and Biochemistry.In this interview, Antony discusses translating academic IP into a commercial device, choosing early clinical sites to balance speed and learning, managing non-dilutive funding as a long-term discipline, and outlines the most important responsibilities of an early-stage medtech CEO.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Antony Odell, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:06) - How Antony's career centered on translating clinical insights into commercial reality (05:54) - What Echopoint's iKOr does, and why 40% of cath lab patients leave without a diagnosis (12:13) - How Echopoint landed its first U.S. clinical site, and what that means for the company (13:48) - What to assess before spinning out an academic idea, and why clinician input is the first real test (20:14) - Why Echopoint chose Barts over typical sites for its first-in-human study (22:58) - How getting too close to one clinical site can lead to dangerous groupthink (30:54) - Why non-dilutive funding belongs on the board agenda permanently (39:54) - How CEOs should manage boards, control information flow, and avoid becoming a “glorified note-taker”

May 15, 2026In this special live episode from the AUA Annual Meeting in Washington, D.C., Scott, Mark, and Ray Painter share highlights from the AUA Innovation Nexus program, where emerging companies, investors, and industry leaders are working to bring new urology technologies to market  . The discussion focuses on the growing importance of reimbursement strategy early in product development, the operational and financial realities practices must consider before adopting new technology, and why collaboration between innovators, physicians, and practice teams is critical for success. The episode also explores how efficiency, workflow, and return on investment increasingly drive whether promising technologies ultimately make it into everyday urology practice. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

The GPonline team talks about collective action, after the BMA GP committee narrowly voted in favour of the move, what that action involves and what needs to happen to resolve the dispute.They look at the practice-level reimbursement scheme for GPs, how that is going to work and some of the issues and challenges the scheme could present.And they discuss some late changes to the network contract DES - the contract that governs how primary care networks work - which will allow ICBs to introduce local variations to help develop neighbourhoods and what that could all mean in practice.In our good news story this week, Emma reflects on a conference on tackling health inequalities she attended this week and the great work going on in many local communities.This episode was presented by GPonline editor Emma Bower, deputy editor Nick Bostock and senior reporter Kimberley Hackett. It was produced by Czarina Deen.Useful linksBMA lays out collective action roadmap and escalation planWill GPs unite behind collective action?NHS Modernisation Bill to introduce single patient recordPractice-level GP reimbursement scheme limited to salaried GPsRestrictive GP contract changes 'will not boost access'Could new PCN rules make neighbourhood contracts redundant?PCNs should refuse contract variations if work is not properly funded, says BMA Hosted on Acast. See acast.com/privacy for more information.

Is the Merit-based Incentive Payment System (MIPS) fulfilling its intended purpose, or is it just causing headaches? Dr. George Williams and Joe Reyes join host Dr. Andrew Pouw to share their expertise and experience with MIPS, including its evolultion from prior medical cost control policies and how ophthalmologists can use the IRIS Registry to meet reporting requirements.  For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts

In this episode, Jen explains what California law requires when employees use personal cell phones for work and why employers still get it wrong, especially with remote and hybrid teams. She covers where compliance fails, how liability adds up, and the practical, defensible approaches that actually work, including stipends, reimbursements, and policy language that holds up.

In this week's episode, Jenny Stone and Katie Singer discuss the new GP reimbursement scheme for 2026/27. They discuss how much practices could claim for reimbursement of an additional salaried GP and what is the eligibility of this scheme. Here is the link referred to in the episode where you can check how much your practice could claim under the scheme: https://haresign.net/tools/gp-reimbursement/ RBP are one of the leading medical specialist firms of chartered accountants in the UK. They have over 30 years' experience in the medical field and they will be sharing their broad and experienced knowledge through their fortnightly Accountancy on Prescription podcasts. Listeners who will be interested in subscribing to these informative and relevant shows are doctors in general practice, locum doctors, hospital consultants, practice managers and PCNs. RBP can be contacted via their website, www.rbp.co.uk, by email info@rbp.co.uk, or call 020 8370 7777. We are always here to help. The content of RBP's podcasts has been obtained from, or is based on, sources that we believe to be accurate and reliable. Although reasonable care has been taken in gathering the necessary information, we cannot guarantee the accuracy or completeness of any information we broadcast in our shows. We accept no liability for any errors or omissions in information provided by the RBP team or their guest speakers. You should always carry out your own independent verification of facts and data prior to making any investment, legal or tax decisions.

In this episode of Medsider Radio, we sat down with Kurt Jacobus, co-founder and CEO of restor3d.restor3d provides patient-specific orthopedic implants using 3D printing and advanced software.Kurt has over two decades of experience in medtech entrepreneurship, including successful exits to Enovis and NuVasive. Prior to his career in medical devices, Kurt was a consultant at McKinsey & Company. He holds a PhD in Mechanical Engineering and is an Adjunct Professor at Georgia Tech. In this interview, Kurt discusses how restor3d used the FDA's 520(b) pathway to generate revenue and regulatory proof simultaneously, why self-regulating beyond FDA requirements makes submissions a competitive barrier, and how to approach investor relationships and board construction with long-term thinking.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Kurt Jacobus.KEY MOMENTS FROM THE INTERVIEW(03:21) - How Kurt went from wanting to build race cars to 20 years of orthopedic entrepreneurship (06:03) - How restor3d's patient-specific implants challenge the “8 sizes fit 8 billion people” model (15:36) - Why early-stage companies should “ring the cash register” as soon as possible (17:16) - How a 520(b) pathway helped restor3d generate revenue before full FDA clearance (31:48) - How restor3d treats every FDA submission like a PhD thesis and holds itself to standards beyond what regulators ask for (35:24) - What Kurt learned from restor3d's limited market release (40:03) - How Kurt raised is last$100M+ round, and why fundraising is really a networking game (45:13) - What makes a great board, and how the wrong one can quietly derail a company

May 8, 2026In this episode, Scott, Mark, and Dr. Ray Painter discuss the growing wave of innovation in urology and why reimbursement strategy must be part of the conversation from day one. Ahead of the AUA Innovation Nexus meeting in Washington, D.C., the team explores how new technologies move from concept to clinical adoption—and the reimbursement hurdles that can slow that process down. The discussion covers coding, coverage, payer adoption, workflow planning, AI-driven practice tools, and the importance of building a realistic business plan before introducing new technology into a practice. The key takeaway: exciting technology alone is not enough—successful adoption requires clinical value, operational readiness, and a clear reimbursement strategy. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

In this episode of Medsider Radio, we sat down with Alfred Griffin, co-founder and CEO of LightForce.LightForce is the developer of the world's first fully customized 3D-printed bracket system directly personalized for each patient's digital treatment plan.Alfred holds a DMD and PhD in Craniofacial Biology from the Medical University of South Carolina and completed his orthodontic residency at Harvard School of Dental Medicine, where he currently serves as faculty and the Board of Fellows. An ABO-certified practicing orthodontist, he continues to see patients every month while running the company.In this interview, Alfred shares how applying existing technology to an overlooked market can unlock a larger opportunity, how adoption friction is a design problem, and why scaling a new category requires treating operations as a core product investment.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Alfred Griffin.KEY MOMENTS FROM THE INTERVIEW(02:43) - How growing up in a family of dentists shaped Alfred's path into orthodontics (07:41) - How LightForce uses digital planning and 3D printing to create fully customized braces (08:48) - Why LightForce isn't a brilliant idea, but an obvious fix for the teen braces market that aligners missed (12:19) - How LightForce is like Google Maps for teeth, eliminating detours and removing inefficiencies (17:30) - How Alfred built LightForce around his clinical strengths and hired for experience to round out the gaps (30:56) - The 3-part secret to LightForce adoption by physicians (36:42) - How Alfred approaches fundraising, matching investors to the company's stage and needs (41:51) - About LightForce's digital factories and why they're the company's core moat

Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: Gary L. Roth, DO, “Fact Check: Drug Pricing Savings Are the Lifeline to Community Healthcare Services,” April 30, 2026, https://www.mha.org/newsroom/fact-check-drug-pricing-savings-are-the-lifeline-to-community-healthcare-services/, Michigan Health and Hospital Association.  American Hospital Association, “AHA urges HRSA to act as Eli Lilly threatens 340B discounts over claims data submission policy,” April 27, 2026, https://www.aha.org/news/headline/2026-04-27-aha-urges-hrsa-act-eli-lilly-threatens-340b-discounts-over-claims-data-submission-policy.  American Hospital Association, “Washington Post publishes AHA letter in response to anti-340B editorial,” April 22, 2025, https://www.aha.org/news/headline/2026-04-22-washington-post-publishes-aha-letter-response-anti-340b-editorial. Jennifer Wessel, JD, MPH, “Commercial Insurers' Payments to Hospitals Closer to Medicare Rates in Arkansas Than in Any Other State,” May 15, 2024, https://achi.net/newsroom/commercial-insurers-payments-to-hospitals-closer-to-medicare-rates-in-arkansas-than-in-any-other-state/, Arkansas Center for Health Improvement. Tess Vrbin, “Low reimbursement rates force Arkansas hospitals to scale back services,” April 21, 2026, https://arkansasadvocate.com/2026/04/21/low-reimbursement-rates-force-arkansas-hospitals-to-scale-back-services/, Arkansas Advocate. Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com.

Contact us and share your opinionJoin Andy and Gandhi for the latest on GP reimbursement scheme, and collective action in General practiceSFE details: https://assets.publishing.service.gov...PCN DES contract: https://www.england.nhs.uk/publicatio...Guidance B:  https://www.england.nhs.uk/publicatio...BMA response: https://www.bma.org.uk/gpcontract?utm...Boost your triage skills with our dynamic 5-session live webinar course, tailored for primary care clinicians. Led by Dr. Gandalf and Dr. Ed Pooley, this comprehensive training covers all facets of remote patient triage—digital, on-call, and more. Gain practical knowledge, exclusive tips, and direct access to our experts through open Q&A sessions. Elevate your ability to manage primary care challenges effec Join Dr Mike as he shares how to get started and fly using EMIS to make your life easier with this clinical systembit.ly/EMIScourse

The White House wants to revamp federal contracting practices by making cost-reimbursement structures the exception, not the rule, per an executive order signed Thursday. President Donald Trump's order calls on the federal government to view fixed-price contracts with performance-based considerations as “the default and preferred method of procurement.” Department of Veterans Affairs Secretary Doug Collins told lawmakers Thursday that the VA's beleaguered electronic health record modernization efforts have turned a corner with the successful rollout of the system this month at four Michigan facilities. Collins said the April 11 deployment of the EHR at hospitals in Detroit, Ann Arbor, Battle Creek and Saginaw “has been phenomenal, even by industry standard.” The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast  on Apple Podcasts, Soundcloud, Spotify and YouTube.

The FY 2027 SNF Proposed Rule may only be 40 pages long… but the implications for skilled nursing operators are massive.In this episode of Gravity Healthcare Hacks, Melissa Brown breaks down the biggest takeaways from the proposed rule and explains what SNF leaders should be paying attention to right now — including reimbursement changes, PDPM case mix concerns, therapy adjustments, quality reporting updates, and why CMS is signaling increased scrutiny around MDS coding and documentation.Melissa also walks through: The proposed 2.4% reimbursement increase — and why many operators feel it falls short  CMS concerns around “case mix creep” under PDPM  Proposed payment reductions to Speech, Nursing, and NTA  Why therapy components may actually increase  What operators should be advocating for before the June 1, 2026 comment deadline  How future all-payer MDS reporting could reshape quality visibility  The growing importance of Medicare Advantage quality outcomes  Why now is the time to audit your MDS processes and documentation If you operate a SNF, manage reimbursement, oversee MDS, or lead clinical operations, this is an episode you do not want to miss.Read more and access additional insights from this episode here: https://gravityhealthcareconsulting.com/gravity-healthcare-hacks-podcast/fy-2027-snf-proposed-ruleNeed help auditing your MDS processes, PDPM accuracy, or reimbursement strategy?Visit Gravity Consulting or contact Melissa Brown and the Gravity team to learn how we help SNFs improve reimbursement accuracy, operational performance, and clinical outcomes.Connect with Gravity Consulting: • Website: https://gravityconsulting.com • Contact Melissa Brown: https://gravityhealthcareconsulting.com/schedule-a-consultation • LinkedIn: https://www.linkedin.com/company/gravityhealthcareconsultingThanks for listening to Gravity Healthcare Hacks. Be sure to subscribe, leave a review, and share this episode with another healthcare leader navigating the changing SNF landscape.Support the show

The Medicaid provider says it will recoup "overpayments" retroactively.

Ready to shake up hip pain management? In this episode of BackTable MSK, we unpack how embolization is opening a new frontier for patients caught between conservative care and surgery. Interventional radiologist Dr. Kavi Krishnasamy hosts Brazilian interventionalists, Dr. Mateus Correa and Dr. Joaquim Filho, to discuss hip embolization for Greater Trochanteric Pain Syndrome (GTPS) and early hip Osteoarthritis (OA). The doctors highlight building multidisciplinary referrals, reimbursement, and the availability of embolic agents. They also address pre-procedure workup, including imaging and physical exam findings. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 02:37 - Guest Background in MSK Embolization 08:14 - Availability of Embolics and Preferences in Brazil 10:31 - Reimbursement and Access Hurdles13:55 - Hip Etiologies Treated by Embolization 16:54 - Imaging Workup and the Role of MRI24:23 - Offering Conservative Treatment Options Prior to Embolization 26:52 - Scoring Systems and Physical Exam34:44 - Procedure Access Strategy39:16 - When to Utilize Temporary vs. Permanent Embolics46:34 - Post-Procedure and Follow-Up Guidelines58:05 - Discussion of Current Evidence --- More about this episode At the time of the procedure, Drs. Correa and Filho explain why they prefer certain vascular access points and specify arterial targets, favoring temporary embolic agents due to potential risk of Avascular Necrosis (AVN) of the femoral head. Furthermore, the doctors detail awake procedures with intraprocedural palpation and blush/pain-based endpoints, post-embolization pain flare management, follow-up schedules, and re-treatment criteria; all with consideration for current published evidence. ---Resources Dr. Mateus Correahttps://www.researchgate.net/profile/Mateus-Correa-4 Dr. Joaquim Filhohttps://www.researchgate.net/profile/Joaquim-Da-Motta-Leal-Filho --- BackTable Musculoskeletal (MSK) is the go-to podcast for musculoskeletal radiologists, interventional pain specialists, and orthopedic surgeons.Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Recently retired Sen. Debbie Stabenow, and Dave Totaro, former BAYADA chief government affairs officer, are excited to bring their healthcare expertise and talents to the bipartisan Liberty Partners Group. Reimbursement challenges for the field are nothing new, they said. What keeps Totaro up at night is the dwindling number of home health agencies. There are 10% fewer agencies today than in 2013, he said. Stabenow is pleased with the progress that took place last year with the 2026 home health final rule, which marked the end of permanent adjustments. Now Liberty Partners is working with the administration to help restore home health funding to 2020 levels when the Patient-Driven Groupings Model began. It also is urging the administration to use verifiable data to fight fraud in home health and hospice. Given the harsh Medicaid cuts in the One Big Beautiful Bill Act, 2026 and 2027 promise to be some of the toughest years financially for the field, Totaro said. He also expects home health to experience cuts for 2027 and does not think any major home care legislation will pass before the midterms. Follow us on social media: X: @McKHomeCare Facebook: McKnight's Home Care LinkedIn: McKnight's Home Care Instagram: mcknights_homecare Show contributors:McKnight's Home Care Editor Liza Berger; Debbie Stabenow, senior policy adviser at Liberty Partners Group; and Dave Totaro, principal at Liberty Partners Group Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailIn Part One of this forward-looking series, Chris Comeaux unpacks the foundational challenges shaping the future of hospice and palliative care. Drawing from nearly a decade of strategic research and collaboration with healthcare leaders, he introduces a powerful framework built around eight core challenges that every organization must navigate.  From intensifying competition to shifting reimbursement models, this conversation equips leaders with a clearer lens to anticipate disruption and respond with intention.What emerges is not just a list of problems—but a strategic roadmap.  Chris explores how “hypercompetition” is reshaping referral patterns, how financial pressures demand organizational agility, and why workforce shortages require a complete rethinking of care delivery.  Throughout the episode, the emphasis remains on proactive leadership: understanding the forces at play, asking better questions, and positioning organizations to thrive—not just survive—in a rapidly evolving landscape.Ultimately, this episode serves as a call for healthcare leaders, nonprofit executives, and hospice professionals to rethink traditional models.  By embracing innovation, diversifying services, and aligning care with what patients truly want, organizations can future-proof their mission and remain deeply relevant in the years ahead.  Key TakeawaysThe future of hospice and palliative care is shaped by eight major challenges, including competition, reimbursement, workforce, and demographic shifts.  Hypercompetition is accelerating, including both direct competitors and “substitution” models that can divert referrals.  Reimbursement pressures are expected to tighten, requiring organizations to become more efficient while exploring new revenue models.  Workforce shortages are a structural reality, demanding an “outside-in” approach that aligns staffing with evolving patient needs.  Long-term success depends on organizational ambidexterity—the ability to optimize current operations while innovating new care models simultaneously.  If you're leading in hospice, healthcare, or the nonprofit space, this conversation is just the beginning.  Subscribe to the podcast, in Part Two, where we go deeper into solutions and strategies you can apply immediately. Share this episode with your leadership team, and start the conversation: Are we truly prepared for what's ahead?The Anatomy of Leadership podcast explores the art and science of leadership through candid, insightful conversations with thought leaders, innovators, and change-makers from a variety of industries. Hosted by Chris Comeaux, each episode dives into the mindsets, habits, and strategies that empower leaders to thrive in complex, fast-changing environments. With topics ranging from organizational culture and emotional intelligence to navigating disruption and inspiring teams, the show blends real-world stories with practical takeaways. The goal is simple yet ambitious: to equip leaders at every level with the tools, perspectives, and inspiration they need to lead with vision, empathy, and impact.https://www.teleioscn.org/anatomy-of-leadership

In Part One of this forward-looking series, Chris Comeaux unpacks the foundational challenges shaping the future of hospice and palliative care. Drawing from nearly a decade of strategic research and collaboration with healthcare leaders, he introduces a powerful framework built around eight core challenges that every organization must navigate.  From intensifying competition to shifting reimbursement models, this conversation equips leaders with a clearer lens to anticipate disruption and respond with intention.What emerges is not just a list of problems—but a strategic roadmap.  Chris explores how “hypercompetition” is reshaping referral patterns, how financial pressures demand organizational agility, and why workforce shortages require a complete rethinking of care delivery.  Throughout the episode, the emphasis remains on proactive leadership: understanding the forces at play, asking better questions, and positioning organizations to thrive—not just survive—in a rapidly evolving landscape.Ultimately, this episode serves as a call for healthcare leaders, nonprofit executives, and hospice professionals to rethink traditional models.  By embracing innovation, diversifying services, and aligning care with what patients truly want, organizations can future-proof their mission and remain deeply relevant in the years ahead.  Key TakeawaysThe future of hospice and palliative care is shaped by eight major challenges, including competition, reimbursement, workforce, and demographic shifts.  Hypercompetition is accelerating, including both direct competitors and “substitution” models that can divert referrals.  Reimbursement pressures are expected to tighten, requiring organizations to become more efficient while exploring new revenue models.  Workforce shortages are a structural reality, demanding an “outside-in” approach that aligns staffing with evolving patient needs.  Long-term success depends on organizational ambidexterity—the ability to optimize current operations while innovating new care models simultaneously.  If you're leading in hospice, healthcare, or the nonprofit space, this conversation is just the beginning.  Subscribe to the podcast, in Part Two, where we go deeper into solutions and strategies you can apply immediately. Share this episode with your leadership team, and start the conversation: Are we truly prepared for what's ahead?Co-Host:Cordt Kassner, PhD, Publisher of Hospice & Palliative Care Today & CEO and Founder of Hospice Analytics Host:Chris Comeaux, President / CEO of Teleios, Author of The Anatomy of LeadershipTeleios Collaborative Network   /   https://www.teleioscn.org/tcntalkspodcast

Minnesota lawmakers are still sorting through requests to reimburse cities for unplanned expenses during a surge of immigration agent activity earlier this year.And the Nobles County Board voted this morning to deny a zoning change that would've allowed data centers to be built on farmland in the southwestern Minnesota County.Those stories and more in today's evening update from MPR News. Hosted by Emily Reese. Music by Gary Meister.

Live Demo: How RCM Plus Prioritizes Denials by Predicted Reimbursement Listen to how RCM Plus uses AI to predict denial recoverability, prioritize work by expected reimbursement, and orchestrate human teams around the claims most worth pursuing. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

The 2026 Medicare Physician Fee Schedule (MPFS) final rule provides insight into how the current administration is thinking about value-based reimbursement. Adam Laughton, Shareholder, Greenberg Traurig LLP, speaks with Alex Kirkland, Senior Vice President, Coker Group, about the trajectory of value-based reimbursement and what is happening in traditional Medicare under the 2026 MPFS. They discuss issues related to alternative payment models (APMs) and conversion factors, steps that providers need to take to qualify as an APM (including investments in electronic health records and an analysis of costs versus benefits), and compliance considerations. Alex recently co-authored an article in Health Law Connections magazine about this topic. From AHLA's Physician Organizations Practice Group.Watch this episode: https://www.youtube.com/watch?v=D-ZCaG-clNIRead the Health Law Connections article: https://www.americanhealthlaw.org/content-library/connections-magazine/article/6e583147-a398-42ab-85c6-293440c564da/Review-of-the-Challenges-and-Requirements-of-BecomLearn more about AHLA's Physician Organizations Practice Group: https://www.americanhealthlaw.org/practice-groups/practice-groups/physician-organizations Essential Legal Updates, Now in AudioAHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.Stay At the Forefront of Health Legal EducationLearn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/. 

In the latest episode of the Public Power Now podcast, Pat Hart, Senior Director for Resilience Programs at APPA, and Giacomo Wray, Operations Services Senior Manager at APPA, offer details on FEMA mutual aid reimbursement and emergency action plan templates that APPA has produced for the benefit of its member utilities. The templates are available on APPA's webpage on mutual aid and emergency response (https://www.publicpower.org/mutual-aid-and-emergency-response).

The Government says it won't set up another dedicated fund to reimburse marae for their work leading up to Cyclone Vaianu, but is encouraging marae to keep in touch with officials on the ground in case they need support. Among them, seven Ngati wai affliated marae in Te Tai Tokerau. Rangatira no Ngatiwai, Aperahama Kerepeti-Edwards spoke to Ingrid Hipkiss.

Full-thickness wounds don't just challenge the body—they expose the entire ecosystem of care. From disrupted dermal architecture to prolonged inflammatory phases, these wounds demand more than routine treatment. They require precision, interdisciplinary strategy, and relentless clinical insight.But here's the truth most people don't say out loud: healing isn't just biological—it's operational.Reimbursement structures, supply chain limitations, advanced therapy costs, and workforce expertise all shape outcomes just as much as tissue viability and vascular integrity. The gap between optimal care and accessible care is where innovation either thrives…or fails.The future of wound care belongs to those who can bridge science with scalability—where clinicians, technologists, and business leaders stop operating in silos and start building systems that actually heal.Because at this level, it's not just about closing wounds.It's about closing gaps in care.#WoundCare #HealthcareInnovation #ClinicalExcellence #MedTech #HealthEconomics #AdvancedWoundCare #HealthcareLeadership #Biotech #PatientOutcomes #DisruptHealthcare #MedicalScience #CareDelivery #FutureOfHealthcare #WoundHealing #HealthcareStrategy

Hundreds of miles of open road can stretch between expectant mothers and the maternity care they need in rural Montana. That's where trained, non-medical professionals called “doulas” can help fill the gap. Montana was set to start reimbursing doulas through Medicaid this year, but federal cuts to the health program have put that plan on ice.

The federal government is still withholding more than $240 million in Medicaid reimbursements to Minnesota, despite approving the state's plan to address fraud concerns. Gov. Tim Walz says the funds should now be released. Thunderstorms, hail and at least one tornado scoured southern Minnesota last night.This is an MPR News Evening update, hosted by Emily Reese. Theme music is by Gary Meister.

Listen to how RCM Plus uses AI to predict denial recoverability, prioritize work by expected reimbursement, and orchestrate human teams around the claims most worth pursuing.Brought to you by www.infinx.com

In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Osteoboost.Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women.Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Laura Yecies.KEY MOMENTS FROM THE INTERVIEW(02:49) - An overview of Laura's background and her transition from consumer tech to medtech (04:53) - The problem Osteoboost is solving — and why bone health remains a massive unmet need (08:31) - How Osteoboost designed its device with the consumer experience in mind (15:44) - Why Osteoboost chose a Class II regulatory pathway over an easier path (19:50) - How to design clinical trials that reflect real-world use and drive patient compliance (25:01) - How early demand and a waitlist validated strong consumer pull before full commercialization (28:48) - Why Laura believed the problem wasn't demand — it was lack of options (33:57) - How patients can become a powerful “sales force” in healthcare (38:20) - Why shifting consumer behavior is making self-pay more viable — with reimbursement coming later

Send us Fan MailIn this thought-provoking episode, Chris Comeaux and Cordt Kassner unpack some of the most pressing forces shaping the future of end-of-life care—private equity, rising healthcare costs, and the accelerating influence of artificial intelligence. Grounded in real-world stories and industry data, the conversation explores a growing tension between the promise of hospice as a gold-standard care model and the operational, financial, and expectation gaps that providers and families are increasingly experiencing. The discussion dives into systemic challenges, including stagnant reimbursement structures, workforce limitations, and a fragmented healthcare ecosystem that often leaves hospice providers navigating complexity without a clear seat at the broader policy table. As private equity and consolidation trends continue to reshape the landscape, the hosts raise critical questions about whether scale enhances or erodes the deeply human, high-touch nature of hospice care.Looking ahead, the episode broadens into a philosophical and strategic lens—examining how AI may redefine not only care delivery, but the very meaning of being human in healthcare. For leaders across hospice, nonprofit, and healthcare sectors, this conversation offers both a warning and a call to action: innovate thoughtfully, protect what works, and ensure the future of end-of-life care remains anchored in purpose, dignity, and humanity.  Key TakeawaysHospice remains a highly effective and compassionate care model—but growing expectation gaps between families and providers are creating friction.Reimbursement and funding structures have not kept pace with inflation, limiting the ability to deliver comprehensive support.The healthcare system's pricing inconsistencies and payer mix distortions are creating downstream pressure on hospice providers.Despite consolidation trends, hospice remains a highly fragmented industry, raising important questions about private equity's role and impact.AI is poised to transform care delivery—but also introduces ethical questions about consciousness, purpose, and the human role in care.(This episode is a Top News Stories of Month March 2026)Co-Host:  Cordt Kassner, PhD, Publisher of Hospice & Palliative Care Today & CEO and Founder of Hospice AnalyticsHost:  Chris Comeaux, President / CEO of TELEIOS, author of The Anatomy of LeadershipThe Anatomy of Leadership podcast explores the art and science of leadership through candid, insightful conversations with thought leaders, innovators, and change-makers from a variety of industries. Hosted by Chris Comeaux, each episode dives into the mindsets, habits, and strategies that empower leaders to thrive in complex, fast-changing environments. With topics ranging from organizational culture and emotional intelligence to navigating disruption and inspiring teams, the show blends real-world stories with practical takeaways. The goal is simple yet ambitious: to equip leaders at every level with the tools, perspectives, and inspiration they need to lead with vision, empathy, and impact.https://www.teleioscn.org/anatomy-of-leadership

In this thought-provoking episode, Chris Comeaux and Cordt Kassner unpack some of the most pressing forces shaping the future of end-of-life care—private equity, rising healthcare costs, and the accelerating influence of artificial intelligence. Grounded in real-world stories and industry data, the conversation explores a growing tension between the promise of hospice as a gold-standard care model and the operational, financial, and expectation gaps that providers and families are increasingly experiencing. The discussion dives into systemic challenges, including stagnant reimbursement structures, workforce limitations, and a fragmented healthcare ecosystem that often leaves hospice providers navigating complexity without a clear seat at the broader policy table. As private equity and consolidation trends continue to reshape the landscape, the hosts raise critical questions about whether scale enhances or erodes the deeply human, high-touch nature of hospice care.Looking ahead, the episode broadens into a philosophical and strategic lens—examining how AI may redefine not only care delivery, but the very meaning of being human in healthcare. For leaders across hospice, nonprofit, and healthcare sectors, this conversation offers both a warning and a call to action: innovate thoughtfully, protect what works, and ensure the future of end-of-life care remains anchored in purpose, dignity, and humanity.  Key TakeawaysHospice remains a highly effective and compassionate care model—but growing expectation gaps between families and providers are creating friction.Reimbursement and funding structures have not kept pace with inflation, limiting the ability to deliver comprehensive support.The healthcare system's pricing inconsistencies and payer mix distortions are creating downstream pressure on hospice providers.Despite consolidation trends, hospice remains a highly fragmented industry, raising important questions about private equity's role and impact.AI is poised to transform care delivery—but also introduces ethical questions about consciousness, purpose, and the human role in care.(This episode is a Top News Stories of Month March 2026)Co-Host:  Cordt Kassner, PhD, Publisher of Hospice & Palliative Care Today & CEO and Founder of Hospice AnalyticsHost:  Chris Comeaux, President / CEO of TELEIOS, author of The Anatomy of LeadershipTeleios Collaborative Network   /   https://www.teleioscn.org/tcntalkspodcast

In this episode of Medsider Radio, we sat down with Stephen Belcher, co-founder and CEO of Secure Closure.Secure Closure is developing Quattro-Close, a device designed for large-bore femoral access sites.Trained as a veterinarian, Stephen has spent more than 25 years in the medical device industry, with deep experience in vascular access and closure technologies. He previously held commercial and marketing roles at Abbott Vascular, Edwards Lifesciences, and Teleflex, where he was involved in launching key closure devices, including ProGlide, StarClose, SAPIEN 3, and MANTA.In this interview, Stephen discusses what actually drives physician adoption in high-stakes procedural fields, how real-world clinical and patient challenges should shape device design decisions, and what early-stage fundraising looks like when traditional medtech VCs are increasingly committing capital at later stages.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Stephen Belcher.KEY MOMENTS FROM THE INTERVIEW(02:52) - An overview of Stephen Belcher's background and the journey that led him to founding Secure Closure (08:04) - How Quattro-Close works, using a purse-string suture and extravascular clip for reliable closure and artery preservation (13:53) - Stephen's lessons learned from large strategics and how he simplifies them for a startup (19:22) - How Stephen spent nearly a decade iterating on the device through failures, funding gaps, and small incremental progress (23:36) - Why physician adoption depends on consistent outcomes, not early excitement or new features (28:10) - How Quattro-Close is designed around the real unmet need, reducing complications while preserving the artery for future procedures (34:14) - His approach to first-in-human, site selection, and generating data that can stand up to FDA scrutiny (40:31) - How Stephen navigates early fundraising

In this episode of Medsider Radio, we sat down with Daniel Estay, founder and CEO of SonoVascular.SonoVascular has developed a novel mechanical-pharmaco ultrasound facilitated thrombectomy system, SonoThrombectomy, that utilizes microbubble-mediated cavitation as a core enabling mechanism to remove blood clots more effectively.Dan has over 35 years of global medtech experience, including business development roles at Johnson & Johnson, where he worked on deals that helped create the world's first drug-eluting stent, and six years leading Abbott's cardiovascular device business across Asia-Pacific and Japan. He also serves as a Mentor-in-Residence at Duke University's New Ventures group.In this interview, Dan discusses how to evaluate whether a medtech opportunity is commercially viable beyond technical feasibility, how trust and long-standing relationships matter more than geography when selecting first-in-human sites, and why cap table strategy requires deliberate thinking from the earliest stages — including when to transition from convertible notes to priced rounds.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Daniel Estay.KEY MOMENTS FROM THE INTERVIEW(02:52) - An overview of Dan Estay's background and the journey that led him to SonoVascular (08:04) - The core idea behind SonoVascular — combining mechanical and pharmacological therapy to treat thrombosis (13:33) - Why differentiation alone isn't enough, and how Dan evaluates market size and viability before building (18:38) - The four risks every medtech founder should assess: technical, clinical, regulatory, and market (21:55) - Why Dan chose Chile for SonoVascular's FIH study and what he looks for in a clinical trial site (29:05) - Why Dan would rethink his use of convertible notes and approach the cap table more strategically (38:28) - Why grants should supplement your funding strategy, not lead it (42:46) - What Dan looks for when hiring for startups

Jordan Pollack, biomedical engineer, entrepreneur and CEO of Sub-Q Bionics. Jordan began his career at Boston Scientific, later founded VeinWay in Israel and is now focused on building a new treatment paradigm for lymphoedema in cancer survivors.In this episode, we explore what actually creates momentum in MedTech, from networking with intent to building the resilience needed to survive the founder journey. Jordan shares why conferences alone rarely deliver results, how warm introductions and targeted roadshows outperform generic networking and what he had to unlearn after leaving corporate structure behind to become a startup CEO. He also offers a brutally honest take on entrepreneurship, explaining why the role is not for everyone and why persistence, resilience and equanimity matter more than titles or ambition alone.We also go deep into the story behind Sub-Q Bionics and why Jordan chose to focus on lymphoedema, particularly in women recovering from cancer treatment. He explains the clinical reality of the disease, the lack of meaningful treatment options beyond maintenance, and why reimbursement, not just good technology, is often the deciding factor in whether a device company succeeds. Along the way, he shares sharp insights on women's health being chronically underfunded, the differences between the U.S. and Israeli startup ecosystems, and why mission-led companies are far more likely to stay the course when things get hard.Timestamps[00:00:32] Why Generic Conferences Rarely Create Real MedTech Opportunity[00:02:05] How Networking Shaped Jordan's Move from Boston Scientific to Israel[00:03:29] What Corporate MedTech Taught Him and What He Had to Unlearn[00:05:54] Why Being a Founder Is Not for Everyone[00:08:49] The Origin of Sub-Q Bionics and the Shift Toward True Disease Treatment[00:11:53] What Lymphoedema Actually Is and Why It Is So Devastating[00:14:06] Why Women's Health Remains Underfunded and Where Innovation Is Emerging[00:18:25] Why Reimbursement Matters More Than Technology Alone[00:20:58] U.S. vs Israel: Two Very Different Startup Ecosystems[00:25:10] Balancing Founder Life, Health, Travel and RelationshipsConnect with Jordan - ⁠https://www.linkedin.com/in/jordan-pollack-81464827/Learn more about Sub-Q Bionics - ⁠⁠https://subqbionics.com/Get in touch with Karandeep Badwal - ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/karandeepbadwal/ ⁠⁠⁠⁠⁠⁠⁠Follow Karandeep on YouTube - ⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@KarandeepBadwal⁠⁠⁠⁠⁠⁠⁠Subscribe to the Podcast

Jim and Chris discuss listener emails, opening with listener PSAs on Medicare Advantage HSA reimbursement eligibility, then moving into questions on Social Security beneficiary rules and finishing their look at conduit trusts for IRAs. (7:00) A listener asks whether Social Security benefits can be passed on to a significant other. (28:00) The guys continue from last week with a listener’s multi-part question on whether a conduit trust should be structured to distribute RMDs before allowing any additional withdrawals — as a strategy for controlling how beneficiaries access inherited IRA funds. The listener also asks what else could trigger a large tax bill in that setup, and whether a conduit trust provides creditor protection. (1:15:30) George asks for the follow-up promised at the end of a recent episode — specifically, the better approach for having a trust inherit an IRA when you’re concerned about an heir mismanaging the funds. The post HSA Reimbursement, Social Security, Conduit Trusts: Q&A #2612 appeared first on The Retirement and IRA Show.

The nurse anesthesia profession is navigating a period of rapid change. From reimbursement cuts and workforce shortages to evolving practice models and federal policy battles, the decisions being made today will shape the future of CRNAs for decades to come. In this special live taping recorded at the West Virginia Association of Nurse Anesthesiology meeting, Sharon sits down with AANA President Jeff Molter to discuss the biggest challenges facing the profession and how CRNAs can stay engaged in protecting their future. Here's some of what you'll hear in this episode:

Indiana's Family and Social Services Administration could end Medicaid drug reimbursement for qualified health centers across the state. Legislation that would have defined the words male and female in state law — and restrict birth certificate gender marker changes — failed this past session. A plan to build a four billion dollar, 130-acre data center on the southwest side of Marion County was approved Wednesday by the Metropolitan Development Commission. Planned Parenthood will close two Indianapolis clinics, leaving its Georgetown Road facility as the only local branch of the nationwide organization. The University of Notre Dame says families with incomes under 150-thousand-dollars will pay zero tuition, starting next school year. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Zach Bundy, with support from News Director Sarah Neal-Estes.

In this episode of Medsider Radio, we sat down with Matthias Hofmann, CEO of Eyebot.Eyebot is commercializing retail kiosks that deliver quick, efficient vision testing.Before Eyebot, Matthias led product development at Formlabs and served as an R&D lead at EyeNetra, where he helped bring the first smartphone-based vision test to market. He holds a Ph.D. in Electrical Engineering with graduate work in vision science and optics. In this interview, Matthias discusses how early missteps informed Eyebot's strategy, how he proved demand before raising capital, and how iterative clinical studies established commercial credibility — along with his unconventional advice on fundraising.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Matthias Hofmann.KEY MOMENTS FROM THE INTERVIEW(02:53) - Overview of Matthias's background and the journey that led him into vision care startups (05:58) - Lessons from solving the right problem the wrong way at EyeNetra (08:44) - Why Eyebot chose a kiosk interface instead of smartphone vision testing (11:08) - How Eyebot designed its system to deliver accurate prescriptions in about 90 seconds (18:17) - How Eyebot proved demand with a rough prototype and a “Free Vision Test” sign in a Boston mall (29:01) - How clinical studies and iteration built the evidence retailers needed to trust the technology (33:17) - What commercialization revealed about consumer behavior in eyewear retail (37:07) - Matthias's fundraising advice: run your raise over Zoom and don't lead with your pitch deck

In this episode of Medsider Radio, we sat down with Massimiliano (Max) Colella, CEO of CMR Surgical.CMR Surgical is developing Versius, a surgical robot designed to make minimally invasive procedures more accessible across specialties.Max brings more than three decades of healthcare leadership experience spanning medtech and hospital systems. He previously held leadership roles at Johnson & Johnson and Smith & Nephew across Europe, Asia Pacific, and the Middle East, and later served as CEO of Evercare Group, a TPG portfolio company.In this interview, Max discusses how to prioritize capital allocation between platform development and product line expansion, when internal processes need restructuring, the importance of having the right culture, and why undertaking market research ahead of launching into a new market is crucial. He also shares his approach to hiring — and on maintaining clear board governance boundaries.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Max Colella. KEY MOMENTS FROM THE INTERVIEW(03:08) - An overview of Max's background and the journey that led him to CMR Surgical (06:53) - Why Max chose surgical robotics — and how Versius is designed to differentiate from existing systems (16:18) - How Max restructured internal processes at CMR to eliminate large-company bureaucracy (21:09) - How market research reshaped CMR's U.S. strategy beyond ambulatory surgery centers (28:48) - Max's capital allocation philosophy: prioritize system performance and stability before expanding capabilities (32:19) - Max's take on Techmed and the future of robotics (36:36) - Why clearly defined roles between board and management are critical for governance (41:10) - Max's philosophy around hiring for mindset over skill

Arthur Spalding, TAMM Net, Inc., contract research organization, on FDA Approval, Clinical Trials, and Reimbursement for Medical Devices and Biotech (North Fulton Business Radio, Episode 944) On this episode of North Fulton Business Radio, host John Ray welcomes Arthur Spalding, President of TAMM Net, Inc., a boutique contract research organization that helps biomedical inventors and companies […]

Book a call: https://remnantfinance.com/calendar ! Out Print the Fed with 1% per week: https://remnantfinance.com/optionsEmail us at info@remnantfinance.com or visit https://remnantfinance.com for more informationFOLLOW REMNANT FINANCEYoutube: @RemnantFinance (https://www.youtube.com/@RemnantFinance )Facebook: @remnantfinance (https://www.facebook.com/profile.php?id=61560694316588 )Twitter: @remnantfinance (https://x.com/remnantfinance )TikTok: @RemnantFinanceDon't forget to hit LIKE and SUBSCRIBE_____________________________Most people don't think about long-term care until they're forced to and by then, it's often too late to get coverage. The statistics are stark: there's a 68% chance any American will need long-term care at some point, and for couples, that number jumps to nearly 90%. Yet most families never have the conversation until a health event forces their hand.In this episode, Hans sits down with Travis McBride — fellow Navy helicopter pilot turned insurance strategist — to break down everything you need to know about long-term care planning.Chapters: 00:00 – Opening segment 02:35 – Travis's background04:50 – What the brokerage does and who they serve 13:40 – Long-term care 101: statistics and why it matters 16:45 – The three ways to fund long-term care 17:20 – Traditional LTCI: how it works and the use-it-or-lose-it problem 18:50 – How carriers mispriced policies in the 90s and 2000s 24:10 – The premium increase trap: stuck and uninsurable 25:20 – Are the premiums guaranteed? 35:05 – Life insurance with an LTC rider38:50 – The six activities of daily living explained 43:05 – Hybrid/asset-based policies: repositioning vs. spending 45:15 – How leverage works inside a hybrid policy 52:30 – Reimbursement vs. cash indemnity55:45 – Who should be thinking about this and when 1:01:25 – What Medicare actually covers and what it doesn't 1:07:15 – The Washington State payroll tax 1:16:25 – How to connect with Travis Key Takeaways:Ask one question before signing anything: are the premiums guaranteed? Traditional long-term care policies were mispriced in the 90s and early 2000s, and carriers have been sending premium increase notices ever since. Know how your benefits are paid before you need them. Reimbursement policies require receipts and ongoing claims filings every month. Cash indemnity policies cut you a check once you qualify and let you use it however you want.Self-insuring isn't insurance — it's just liquidation. Having enough assets to cover a long-term care event sounds like a plan until you run the math. A nursing facility in Southern California runs $6,000 to $15,000 a month, and that's today's cost. Hybrid policies reposition assets — they don't just spend them. Unlike traditional LTCI where premiums vanish if you never file a claim, hybrid linked-benefit policies give you liquidity, control, and a residual death benefit. The best time to have this conversation is before someone needs to. The sweet spot for getting coverage is 45 to 60, when you're still healthy enough to qualify and premiums haven't become prohibitive. By 65, you're entering the game late. 

In this episode, Patrick Velliky, Chief External Affairs Officer at HaloMD, breaks down the latest trends in health care policy, payer consolidation, and the No Surprises Act. He explains how providers can navigate reimbursement challenges, reduce administrative burdens, and focus on delivering care while staying independent.This episode is sponsored by HaloMD.